Henrik Møller

Henrik Møller

Auto-generated profile, based on publicly available information

Henrik Møller

Department of Cancer Epidemiology and Population Health, King's College London, King's Health Partners, London, UK

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in The Lancet Oncology
Verified
Journal Article
Open access
JCJack Cuzick
Jack Cuzick
GSGregory P. P Swanson
Gregory P. P Swanson
GFGabrielle Fisher
Gabrielle Fisher
ABArthur R Brothman
Arthur R Brothman
DBDaniel M Berney
Daniel M Berney
SSSteven Stone
Steven Stone
Optimum management of clinically localised prostate cancer presents unique challenges because of the highly variable and often indolent natural history of the disease. To predict disease aggressiveness, clinicians combine clinical variables to create prognostic models, but the models have limited accuracy. We assessed the prognostic value of a predefined cell cycle progression (CCP) score in two cohorts of patients with prostate cancer. We measured the expression of 31 genes involved in CCP with quantitative RT-PCR on RNA extracted from formalin-fixed paraffin-embedded tumour samples, and created a predefined score and assessed its usefulness in the prediction of disease outcome. The signature was assessed retrospectively in a cohort of patients from the USA who had undergone radical prostatectomy, and in a cohort of randomly selected men with clinically localised prostate cancer diagnosed by use of a transurethral resection of the prostate (TURP) in the UK who were managed conservatively. The primary endpoint was time to biochemical recurrence for the cohort of patients who had radical prostatectomy, and time to death from prostate cancer for the TURP cohort. After prostatectomy, the CCP score was useful for predicting biochemical recurrence in the univariate analysis (hazard ratio for a 1-unit change [doubling] in CCP 1·89; 95% CI 1·54-2·31; p=5·6×10(-9)) and the best multivariate analysis (1·77, 1·40-2·22; p=4·3×10(-6)). In the best predictive model (final multivariate analysis), the CCP score and prostate-specific antigen (PSA) concentration were the most important variables and were more significant than any other clinical variable. In the TURP cohort, the CCP score was the most important variable for prediction of time to death from prostate cancer in both univariate analysis (2·92, 2·38-3·57, p=6·1×10(-22)) and the final multivariate analysis (2·57, 1·93-3·43; p=8·2×10(-11)), and was stronger than all other prognostic factors, although PSA concentration also added useful information. Heterogeneity in the hazard ratio for the CCP score was not noted in any case for any clinical variables. The results of this study provide strong evidence that the CCP score is a robust prognostic marker, which, after additional validation, could have an essential role in determining the appropriate treatment for patients with prostate cancer. Cancer Research UK, Queen Mary University of London, Orchid Appeal, US National Institutes of Health, and Koch Foundation.

1 December 2003 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
MSM. Sant
M. Sant
TAT. Aareleid
T. Aareleid
FBF. Berrino
F. Berrino
MLM. Bielska Lasota
M. Bielska Lasota
PCP. M. Carli
P. M. Carli
DLD. Lisi
D. Lisi
1Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; 2Institute of Experimental and Clinical Medicine and Estonian Cancer Registry, Tallinn,

14 August 2012 in British Journal of Cancer
Verified
Journal Article
Open access
JMJ Maddams
J Maddams
MUM Utley
M Utley
HMH Møller
H Møller
Background: Methods: Results: Conclusion:

16 July 2007 in Oncogene
Verified
Journal Article
Closed access
PDF file
GAG Attard
G Attard
JCJ Clark
J Clark
LAL Ambroisine
L Ambroisine
GFG Fisher
G Fisher
GKG Kovacs
G Kovacs
OGon behalf of the Transatlantic Prostate Group
on behalf of the Transatlantic Prostate Group

1 January 1990 in European Journal of Cancer and Clinical Oncology
Verified
Journal Article
Closed access
OJO. Møller Jensen
O. Møller Jensen
JEJ. Estève
J. Estève
HMH. Møller
H. Møller
HRH. Renard
H. Renard

1 January 1994 in European Journal of Cancer
Verified
Journal Article
Closed access
HMHenrik Møller
Henrik Møller
AMAnders Mellemgaard
Anders Mellemgaard
KLKnud Lindvig
Knud Lindvig
JOJørgen H. Olsen
Jørgen H. Olsen